Meta-analysis examining the epidemiology of clozapine-associated neutropenia


Learning Objectives:

1. Review the FDA’s termination of the risk evaluation andmitigation (REMS) program for clozapine

2. Explore the background and evolution of clozapineneutrophil monitoring since 1990

3. Discuss implications for clinical practice

PDF icon 1. Sherer MD JC flyer.pdf

Session date: 
06/18/2025 - 12:00pm to 1:00pm EDT
Location: 
Virtual
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
Please login or register to take this course.
Faculty List: 
Program Director(s)

Thomas Wise

has no relevant financial relationships to disclose at this time.
Speaker(s)

Michael Sherer

has no relevant financial relationships to disclose at this time.